Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Langchuangjing granule is a traditional Chinese medicine (TCM) herbal formula developed for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis. It is used as an adjunct to standard Western therapies such as prednisone acetate and hydroxychloroquine. Mechanistically, Langchuangjing exerts immunomodulatory effects by restraining excessive apoptosis of T and B lymphocytes, suppressing autoimmune activity, reducing immune complex deposition, inhibiting inflammatory mediators like ICAM-1, and protecting kidney cells. Preclinical studies suggest it can modulate immune cell function and improve clinical outcomes in SLE patients when combined with conventional treatments[3][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Langchuangjing granule.